They believe that novel genes that encode proteins are potentially useful red flags for early-stage ovarian tumors. Researchers have assembled a panel of known and novel ovarian tumor markers that may form the basis of a cost-effective serologic screening test. A simple test for mad cow disease. They have recently concluded that the test is effective and could help stop infected meat from reaching consumers. Currently the test for BSE is unwieldy and takes up to 2 years to produce results.
Companies combine products.
The package runs Bayer s Quantigene Assays on Zymark s Staccato Workstation. The companies say the combination allows laboratories to choose any gene target, cell type, or design, and implement that information in automated cell-based assays. Probe to detect breast cancer. Expected to come on the market in about 3 years, the Smart Probe screens for cancer indicators in patients with suspicious tumors. It is hoped the device will reduce unnecessary and false-negative biopsies.